-
Lixisenatide (trade name
Lyxumia in the
European Union and
Adlyxin in the U.S. and
manufactured by Sanofi) is a once-daily
injectable GLP-1
receptor agonist...
- glargine/
lixisenatide, sold
under the
brand name
Soliqua among others, is a fixed-dose
combination medication that
combines insulin glargine and
lixisenatide and...
- A10AE07
Insulin icodec A10AE30
Combinations A10AE54
Insulin glargine and
lixisenatide A10AE56
Insulin degludec and
liraglutide A10AF01
Insulin (human) A10BA01...
-
receptor agonists : albiglutide, dulaglutide, exenatide, liraglutide,
lixisenatide,
tirzepatide and semaglutide, the
latter of
which is
marketed under the...
- for head lice, now
owned by
Arbor Pharmaceuticals. –
Diabetes Adlyxin (
Lixisenatide), for type 2
diabetes mellitus.
Admelog (insulin lispro), for type 1...
-
dulaglutide (Trulicity,
manufactured by Eli Lilly),
approved in 2014
lixisenatide (Lyxumia in Europe,
Adlyxin in the
United States,
manufactured by Sanofi)...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
